Germany Exhibition Health (000813): Net Profit Fell More Than 4 In The First Half, And Spent 150 Million Of The Layout Of Industrial Hemp.

After the first half year performance decline of 000813.SZ, the layout of industrial hemp is planned.

In September 7th, the German exhibition Health announced that it is ready to sign the cooperation agreement between the German exhibition great health Limited by Share Ltd and Han Zhong Business Management Group Co., Ltd., Han Ma Investment Group Co., Ltd. and Han Yi Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as Han Zhong Group), Han Ma Investment Group Co., Ltd. (hereinafter referred to as Han Chinese Investment Group) and Han Yi Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as "Han Yi Investment") (hereinafter referred to as Han Yi bio) (hereinafter referred to as Han Yi bio), hereinafter referred to as "cooperation agreement", to jointly layout the industrial MAH industrial chain.

Half a month ago, the company revealed half year report that the first performance decline of German exhibition health in the first half of this year was the result of the company's transformation. Germany exhibition Health said that the reason for the decline in performance was mainly affected by the policy of purchasing quantity, and the unit price of product sales declined.

Changjiang Daily News reporter found that since March this year, the German Health Exhibition for the layout of the industrial hemp industry chain has been frequent, or related to the company's declining performance.

In the first half, net profit fell by more than 4.

In August 24th, German exhibition health disclosure semi annual report shows that in the first half of 2019, German exhibition health revenue reached 922 million yuan, net profit realized 242 million yuan, down 44.50% and 45.48% respectively compared with the same period last year. At the same time, the gross profit margin of the pharmaceutical industry dropped by 5.89%, which basically fell back to the 2016 level that just completed the backdoor listing.

This is not the first performance decline of German exhibition. In the first quarter of this year, the company achieved revenue of 481 million yuan and net profit of 121 million yuan, down 38.92% and 32.09%, respectively, the first decline since 2016.

It is understood that the main business of taidan health is the R & D, production and sale of pharmaceuticals, and its wholly-owned subsidiary, Jialin pharmaceutical, has been ranked the leading position of domestic medicine in many years. According to the China Pharmaceutical Association business data, its main product, "Ai Le", ranks first in the domestic lipid-lowering drugs.

However, this year, due to the formal implementation of the policy of "4+7 City centralized drug purchase", the sales price of arrow products has dropped substantially in the first quarter, and the larger difference between the "volume area" and "non volume area" has a great impact on the overall sales volume and sales volume of the company.

In 2019, the main sale of drugs declined, making the development of German health a great deal of crisis and began a new way out.

150 million of the layout of industrial hemp

In September 7th, the German exhibition Health announced that it would sign a cooperation agreement with Han Zhong Group, hemp investment and Han Yi biology, and jointly lay out the industrial hemp industry chain. The investment of Han Ma and Han Yi are subsidiaries of Han Zhong Group and sun company respectively.

Changjiang Daily reporter found that since March, the German exhibition health and Han Chung group and its subsidiaries have been constantly moving.

In March this year, the German exhibition health and Han Zhong Group and hemp investment signed the framework agreement on equity purchase and comprehensive strategic cooperation (hereinafter referred to as the "framework agreement"). The Han nationality Group pledged its 25% stake in Han Ma investment to Germany's fair and healthy development, and it paid 150 million yuan in good faith.

In May and June, Dezhou health was invested with Han Yi bio to establish Deyi Pharmaceutical Co., Ltd. The business scope of Deyi pharmaceuticals includes pharmaceutical technology, plant extracts and cultivation of Chinese medicinal materials. The company mainly sells food, technology development and transfer, import and export of goods, technology import and export, and also layout industrial hemp and catering industry.

This cooperation agreement shows that the 150 million yuan of sincerity paid by Dezhou health has been invested by shareholders of Deyi Pharmaceutical Co., Ltd. and merry food and Beverage Co., Ltd. in the future.

At present, the development of industrial hemp industry is fast. However, as more and more enterprises enter the field of industrial hemp, the market competition will be more and more intense.